Evidence map›Paper›PMID 30322880›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.

Eshini Panditharatna, Lindsay B Kilburn, Mariam S Aboian, Madhuri Kambhampati, Heather Gordish-Dressman, Suresh N Magge, Nalin Gupta, John S Myseros, Eugene I Hwang, Cassie Kline and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. [Liquid Biopsy Revolutionizes the Precise Management of Tumors Across the Entire Course: Current Situation and Future Prospects].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Observational
  19. Article
  20. Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Eshini PanditharatnaRese arch Center for Genetic Medicine, Children's National Health System, Washington, D.C.
Lindsay B KilburnCenter for Cancer and Blood Disorders, Children's National Health System, Washington D.C.
Mariam S AboianDepartments of Neurology, Pediatrics and Neurosurgery, University of California, San Francisco School of Medicine, San Francisco, California.
Madhuri KambhampatiRese arch Center for Genetic Medicine, Children's National Health System, Washington, D.C.
Heather Gordish-DressmanRese arch Center for Genetic Medicine, Children's National Health System, Washington, D.C.
Suresh N MaggeDivision of Neurosurgery, Children's National Health System, Washington, D.C.
Nalin GuptaDepartment of Neurological Surgery and Pediatrics, University of California San Francisco, San Francisco, California.ORCID 0000-0001-9539-7052
John S MyserosDivision of Neurosurgery, Children's National Health System, Washington, D.C.
Eugene I HwangCenter for Cancer and Blood Disorders, Children's National Health System, Washington D.C.
Cassie KlinePediatric Hematology-Oncology and Neurology, UCSF Benioff Children's Hospital, San Francisco, California.
John R CrawfordDepartment of Neurosciences, UC San Diego School of Medicine, La Jolla, California.ORCID 0000-0002-4100-7001
Katherine E WarrenNational Cancer Institute, NIH, Bethesda, Maryland.
Soonmee ChaDepartment of Radiology, University of California, San Francisco School of Medicine, San Francisco, California.
Winnie S LiangTranslational Genomics Research Institute, Phoenix, Arizona.
Michael E BerensTranslational Genomics Research Institute, Phoenix, Arizona.ORCID 0000-0002-3382-6787
Roger J PackerBrain Tumor Institute, Children's National Health System, Washington, D.C.
Adam C ResnickCenter for Data-Driven Discovery, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Michael PradosDepartments of Neurology, Pediatrics and Neurosurgery, University of California, San Francisco School of Medicine, San Francisco, California.
Sabine MuellerDepartments of Neurology, Pediatrics and Neurosurgery, University of California, San Francisco School of Medicine, San Francisco, California.
Javad NazarianRese arch Center for Genetic Medicine, Children's National Health System, Washington, D.C. jnazarian@childrensnational.org.

Funding

Clinical and Translational Science Institute at Childrens NationalUL1TR001876 · NCATS · CHILDREN'S RESEARCH INSTITUTE · PI BELL, MICHAEL J · 2016 to 2021
$25.6M
U2C Kids First Admin Supplement - data transferU2CHL138346 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI HEATH, ALLISON · 2017 to 2022
$21.5M
Research Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0M
Early Clinical Trials for Children with CNS TumorsZIABC011447 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WARREN, KATHERINE E · 2012 to 2019
$2.1M
NCATS NIH HHS UL1 TR001876NCI NIH HHS T32 CA128583NHLBI NIH HHS U2C HL138346
6 · The paper itself

Abstract

purposePediatric diffuse midline glioma (DMG) are highly malignant tumors with poor clinical outcomes. Over 70% of patients with DMG harbor the histone 3 p.K27M (H3K27M) mutation, which correlates with a poorer clinical outcome, and is also used as a criterion for enrollment in clinical trials. Because complete surgical resection of DMG is not an option, biopsy at presentation is feasible, but rebiopsy at time of progression is rare. While imaging and clinical-based disease monitoring is the standard of care, molecular-based longitudinal characterization of these tumors is almost nonexistent. To overcome these hurdles, we examined whether liquid biopsy allows measurement of disease response to precision therapy. EXPERIMENTAL

designWe established a sensitive and specific methodology that detects major driver mutations associated with pediatric DMGs using droplet digital PCR (

resultsH3K27M was identified in cerebrospinal fluid (CSF) and plasma in 88% of patients with DMG, with CSF being the most enriched for ctDNA. We demonstrated the feasibility of multiplexing for detection of H3K27M, and additional driver mutations in patient's tumor and matched CSF, maximizing the utility of a single source of liquid biome. A significant decrease in H3K27M plasma ctDNA agreed with MRI assessment of tumor response to radiotherapy in 83% (10/12) of patients.

conclusionsOur liquid biopsy approach provides a molecularly based tool for tumor characterization, and is the first to indicate clinical utility of ctDNA for longitudinal surveillance of DMGs.

Indexed as

Biomarkers, TumorLiquid BiopsyAge FactorsBrain NeoplasmsCell-Free Nucleic AcidsCirculating Tumor DNAGliomaHumansMagnetic Resonance ImagingMolecular Diagnostic TechniquesMutationNeoplasm StagingPublic Health SurveillanceBiomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNA

Identifiers

PMID30322880
PMCPMC6279526

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.